Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Triptan migraine treatments and antidepressants: risk of serotonin syndrome

Eric Wooltorton
CMAJ October 10, 2006 175 (8) 874; DOI: https://doi.org/10.1503/cmaj.061217
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Reason for posting: Serotonin syndrome is a rare but serious and sometimes fatal toxidrome characterized by mental, autonomic and neurologic symptoms.

Serotonergic psychotropic medications, including many antidepressants, have long been known to trigger the condition. The US FDA1 has now reported the condition in a number of people taking triptans concurrently with some antidepressants, particularly selective serotonin and serotonin– norepinephrine reuptake inhibitors (SSRIs and SNRIs, respectively).

The drugs: Triptans are used intermittently to abort migraines. They act as selective 5-HT1B and 5-HT1D receptor agonists and lead to cranial vasoconstriction and neuronal inhibition. Along with triptans, a variety of agents (taken alone or in combination) can precipitate serotonin syndrome (Box 1).2–4 The pathophysiology of the condition appears to relate to increased serotonin synthesis (L-tryptophan) or to altered serotonin release, reuptake, catabolism or receptor agonism.3 The reasons for individual susceptibilities are still unclear. About 1 in 7 patients who overdose on antidepressants experience the syndrome.2

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

The symptoms of serotonin syndrome (Box 2)2–5 often have a rapid onset, usually within hours of the initiation or dose change of a drug, but occasionally up to several weeks after. Of note, serotonin syndrome can appear as a mild case in which the patient is afebrile but shivers and experiences no other symptoms beyond tachycardia, diaphoresis, mydriasis, tremor and myoclonus.2

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 2.

No diagnostic test is specific for the condition, but laboratory abnormalities often include metabolic acidosis, elevated muscle enzymes (creatinine phosphokinase, alanine and aspartate aminotransferases, lactic dehydrogenase) and creatinine, disseminated intravascular coagulopathy, leukocytosis and ventricular arrhythmia.2–4

The FDA is aware of 27 cases involving patients taking SSRIs or SNRIs and triptans. In 2 cases, the patients' life was endangered; 13 of the 27 patients were admitted to hospital. Many of these patients had taken the drugs in combination previously, without problems. In 8 cases, recent dose increases or the addition of another serotonergic drug to an SSRI– triptan or SNRI– triptan combination were related to symptom onset, which occurred a median of 1 day (range 10 minutes to 6 days) afterward.1

What to do: Triptans and antidepressants are widely prescribed and have a biologically plausible interaction. Although the risk of serotonin syndrome appears to be low, prescribers of either class of medications should ask patients about medications prescribed elsewhere, to discover any that may interact. Users of triptan in combination with an SSRI or SNRI should be warned of this rare but serious adverse effect. During periods of drug initiation, dose escalation or the addition of another serotonergic agent, patients should be particularly vigilant for symptoms of concern (Box 2) and seek urgent medical attention if any occur. The offending agents should be withdrawn, and patients closely monitored and treated with supportive measures as required.4

REFERENCES

  1. 1.↵
    US Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin– norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). Available: www.fda.gov/CDER/DRUG/InfoSheets/HCP/triptansHCP.htm (accessed 2006 Sept 14).
  2. 2.↵
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Christensen RC. Identifying serotonin syndrome in the emergency department [letter]. Am J Emerg Med 2005;23:406-8.
    OpenUrlPubMed
  4. 4.↵
    Birmes P, Coppin D, Schmitt L, et al. Serotonin syndrome: a brief review. CMAJ 2003;168(11):1439-42.
    OpenUrlFREE Full Text
  5. 5.↵
    Garside S, Rosebush PI. Serotonin syndrome: not a benign toxidrome [letter]. CMAJ 2003;169(6):543.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 175 (8)
CMAJ
Vol. 175, Issue 8
10 Oct 2006
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (p 1013 - 1020)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Triptan migraine treatments and antidepressants: risk of serotonin syndrome
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Triptan migraine treatments and antidepressants: risk of serotonin syndrome
Eric Wooltorton
CMAJ Oct 2006, 175 (8) 874; DOI: 10.1503/cmaj.061217

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Triptan migraine treatments and antidepressants: risk of serotonin syndrome
Eric Wooltorton
CMAJ Oct 2006, 175 (8) 874; DOI: 10.1503/cmaj.061217
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pharyngeal tularemia acquired in an urban setting in Canada
  • Antithrombotic agents in patients with COVID-19
  • Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
Show more Practice

Similar Articles

Collections

  • Topics
    • Drugs: adverse reactions
    • Neurology
    • Psychiatry & mental health: adult

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire